Neonatal conjunctivitis is an inflammation of the eye in newborn babies. At our company, we are committed to advancing the development of innovative vaccines and therapies to combat this infectious disease.
Introduction to Neonatal Conjunctivitis
Ophthalmia neonatorum or neonatal conjunctivitis occurs in babies during the first 30 days after their birth as a result of inflammation of the conjunctiva. It can be the result of multiple infectious as well as non-infectious pathogenic agents, inclusive of Neisseria gonorrhoeae, Chlamydia trachomatis, herpes simplex virus (HSV), irritably chemical agents or even blocked tear ducts. This needs to be treated and controlled effectively to avoid complications such as near complete loss of eyesight, which is seen more often in advanced cases of the infection.
Fig.1 Reference data on the distribution of resistance to different antibiotics. (Kara M., et al., 2018)
Vaccine Development for Neonatal Conjunctivitis
Constructing a suitable vaccination against the causative agents of neonatal conjunctivitis has been under study and clinical trials. A vaccination against this condition can be potentially developed so as to avoid the destructive effects of it through evoking boosting the immune system to protect the body.
Infancy specific immune characteristics which are still developing constitute an immune drawback when trying to create a vaccine against neonatal conjunctivitis and that is a challenge clinics and healthcare units face. Need for augmenting target immune responses has been researched on extensively through adjuvant use and treats vaccine delivery routes and modifications of the antigen formulations.
Therapeutics Development for Neonatal Conjunctivitis
The issue behind developing drugs and therapies for neonatal conjunctivitis rests on clinical pharmacy, microbiology, immunology, pediatrics and ophthalmology. It is important to devise safe and effective therapeutics that would prevent or ameliorate the disease in the newborn.
Antimicrobial Agents
The invention of antimicrobials aims at discovering and developing new formulations for the treatment of the particular infective agents that cause neonatal conjunctivitis. For targetable bacterial infections, antibiotics such as ceftriaxone and erythromycin are employed. Acyclovir, an antiviral agent, is also considered for viral infections.
Systemic and Topical Therapies
It is crucial to make a choice between systemic administration and topical application of these drugs. Systemic administration guarantees sufficient drug levels in the body and topical application minimizes the systemic side effects and aims the rebuke to the site of infection.
Our Services
At our company, we are proud of the extensive portfolio of services aimed at facilitating the development of vaccines and therapies for neonatal conjunctivitis. Our multidisciplinary team involving immunologists, microbiologists, pharmacologists as well as preclinical researchers works in unison to foster creativity and ensure the success of your projects.
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
Disease Models
- N. gonorrheae Induced Conjunctivitis
- Chlamydia Induced Conjunctivitis
- Herpes simplex virus (HSV 2) Induced Conjunctivitis
- Staphylococcus aureus Induced Conjunctivitis
- Streptococcus pyogenes Induced Conjunctivitis
Our approach that is strengthened by strong data and compliance to relevant industry standards guarantees the delivery of results that are reliable and are of a high quality which is crucial to enhancing your pharmaceutical and vaccine development initiatives. If our services are of interest to you, we kindly invite you to contact us so that you can obtain any further details needed and an accurate estimate of the cost.
References
- Kara Mustafa, et al. "The newborn conjunctival flora at the post delivery 24 hours." Journal of Current Ophthalmology 30.4 (2018): 348-352.
- Makker Kartikeya, George N. Nassar, and Evan J. Kaufman. "Neonatal conjunctivitis." (2017).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
